Format

Send to

Choose Destination
Ann Intern Med. 2019 May 21;170(10):682-690. doi: 10.7326/M18-1605. Epub 2019 Apr 23.

Long-Term Weight Loss With Metformin or Lifestyle Intervention in the Diabetes Prevention Program Outcomes Study.

Author information

1
Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, Louisiana (J.W.A., K.M.G.).
2
Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania (E.M.V.).
3
George Washington University Biostatistics Center, Rockville, Maryland (S.L.E.).
4
National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, Arizona (W.C.K.).
5
Colorado School of Public Health, Aurora, Colorado (D.D.).
6
Seattle Epidemiologic Research and Information Center, VA Puget Sound Health Care System, Seattle, Washington (E.J.B.).
7
Columbia University College of Physicians and Surgeons, New York, New York (X.P.).
8
Johns Hopkins University School of Medicine, Baltimore, Maryland (R.R.K.).
9
Lund University Diabetes Centre, Skåne University Hospital, Malmö, Sweden (P.W.F.).
10
University of California, Los Angeles, Los Angeles, California (P.S.).

Abstract

Background:

Identifying reliable predictors of long-term weight loss (LTWL) could lead to improved weight management.

Objective:

To identify some predictors of LTWL.

Design:

The DPP (Diabetes Prevention Program) was a randomized controlled trial that compared weight loss with metformin, intensive lifestyle intervention (ILS), or placebo. Its Outcomes Study (DPPOS) observed patients after the masked treatment phase ended. (ClinicalTrials.gov: NCT00004992 and NCT00038727).

Setting:

27 DPP and DPPOS clinics.

Participants:

Of the 3234 randomly assigned participants, 1066 lost at least 5% of baseline weight in the first year and were followed for 15 years.

Measurements:

Treatment assignment, personal characteristics, and weight.

Results:

After 1 year, 289 (28.5%) participants in the metformin group, 640 (62.6%) in the ILS group, and 137 (13.4%) in the placebo group had lost at least 5% of their weight. After the masked treatment phase ended, the mean weight loss relative to baseline that was maintained between years 6 and 15 was 6.2% (95% CI, 5.2% to 7.2%) in the metformin group, 3.7% (CI, 3.1% to 4.4%) in the ILS group, and 2.8% (CI, 1.3% to 4.4%) in the placebo group. Independent predictors of LTWL included greater weight loss in the first year in all groups, older age and continued metformin use in the metformin group, older age and absence of either diabetes or a family history of diabetes in the ILS group, and higher fasting plasma glucose levels at baseline in the placebo group.

Limitation:

Post hoc analysis; examination of nonrandomized subsets of randomized groups after year 1.

Conclusion:

Among persons with weight loss of at least 5% after 1 year, those originally randomly assigned to metformin had the greatest loss during years 6 to 15. Older age and the amount of weight initially lost were the most consistent predictors of LTWL maintenance.

Primary Funding Source:

National Institutes of Health.

PMID:
31009939
PMCID:
PMC6829283
DOI:
10.7326/M18-1605
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center